[ghc]

Unfortunately my wife leads a team coordinating R&D conversion to manufacturing so I have no idea what I can or cannot say that isn't on the website.

But from my perspective the regulatory process is a lot easier to navigate than the supply chain. Even if you get through all the trials, manufacturing a billion doses and distributing them across a supply chain is a special kind of hard that only companies like Pfizer can handle.

So while BioNTech doesn't need help bringing an oncology therapy to market (it just takes time because cancer is hard), it needs a company like Pfizer to actually get it to patients, both in phase 3 trials and after approvals.